当前位置： SCI文献检索 > BONE MARROW TRANSPLANTATION期刊下所有文献 > Allogeneic haemopoietic cell transplants in Australia, 1996--a multi-centre retrospective comparison of the use of peripheral blood stem cells with bone marrow.

Allogeneic haemopoietic cell transplants in Australia, 1996--a multi-centre retrospective comparison of the use of peripheral blood stem cells with bone marrow.

Abstract：

:A retrospective comparison was carried out on adult patients receiving HLA-identical allogeneic haemopoietic stem cell transplants from siblings in Australia in 1996, comparing bone marrow with G-CSF-mobilised peripheral blood stem cells. A total of 131 transplant recipients from nine centres were included in this study, of whom 79 received bone marrow, 44 blood stem cells and eight both. All but three of the 131 patients had cyclosporin and methotrexate as graft-versus-host disease prophylaxis. The minimum follow-up time for surviving patients is 27 months. Comparisons were carried out between the BM and PBSC groups. There were no significant differences between groups in age, sex, diagnosis, donor characteristics or pretransplant conditioning. Median time to neutrophil recovery of 0.5 x 10(9)/l was 14 days for PBSC recipients, compared to 19 days for marrow recipients (P < 0.0005). median time to platelet recovery of 20 x 10(9)/l was 17 days for PBSC recipients, compared to 28 days for marrow recipients (P < 0.0005). there were no significantly increased risks of either acute or chronic GVHD in the PBSC recipients. there were no significant differences between the groups in the incidence of major transplant-related complications, disease-free survival or overall survival.

journal_name

Bone Marrow Transplant

journal_title

Bone marrow transplantation

authors

Nivison-Smith I,Bradstock KF,Szer J,Durrant S,Dodds A,Hermann R,Schwarer AP,Gibson J,To LB,Arthur C,Australian Bone Marrow Transplant Cooperative Sutdy Group.

doi

10.1038/sj.bmt.1703088

subject

Has Abstract

pub_date

2001-07-01 00:00:00

pages

21-7

issue

1

eissn

0268-3369

issn

1476-5365

journal_volume

28

pub_type

杂志文章,多中心研究

相关文献

BONE MARROW TRANSPLANTATION文献大全
  • Sputum induction as an aid to diagnosis of active cytomegalovirus infection following bone marrow transplantation.

    abstract：:An 8-year-old boy received an allogeneic bone marrow transplant (BMT) for relapsed T cell acute lymphoblastic leukaemia. Because he was seropositive for cytomegalovirus (CMV), serial virological specimens were taken throughout the transplant period, and included those obtained by sputum induction. Sixty-one days follo...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Foot AB,Caul EO,Roome AP,Cornish JM,Catterall JR

    更新日期：1990-04-01 00:00:00

  • Allogeneic and autologous bone marrow transplantation in single centre experience.

    abstract：:Among 290 BMT procedures: 74 AML, 78 ALL, 34 CML, 6 SAA, 3 MDS, 42 HD, 35 NHL, 11 MM, and 7 solid tumours (breast or testis cancer) Allogeneic BMT was performed in 76 patients and ABMT/APBCT in 214 patients. Survival, DFS and relapse curves were calculated using the Kaplan-Meier product limit method. Variables potenti...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Hołowiecki J,Wojnar J,Krawczyk-Kuliś M,Kruzel T,Markiewicz M,Kopera M,Wojciechowska M

    更新日期：1998-12-01 00:00:00

  • Umbilical cord blood stem cell transplantation from unrelated HLA-matched donor in an infant with severe congenital neutropenia.

    abstract：:We report here a 6-month-old boy with severe congenital neutropenia (SCN) successfully treated by cord blood stem cell transplantation (CBSCT) from an unrelated donor. He had recurrent life-threatening respiratory infection due to severe neutropenia that was refractory to recombinant human granulocyte colony-stimulati...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1704439

    authors： Mino E,Kobayashi R,Yoshida M,Suzuki Y,Yamada M,Kobayashi K

    更新日期：2004-05-01 00:00:00

  • Autologous blood cell transplantation in B-CLL: response to chemotherapy prior to mobilization predicts the stem cell yield.

    abstract：:Successful stem cell mobilization and collection is possible in B-CLL after a favorable response to preceding chemotherapy, and also after treatment with the new nucleoside analogues fludarabine and cladribine. A poor response, on the other hand, seemed to predict a mobilization failure. CD34+ cell selection resulted ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1700730

    authors： Itälä M,Pelliniemi TT,Rajamäki A,Remes K

    更新日期：1997-04-01 00:00:00

  • Effect of in vivo therapy with a CD8 monoclonal antibody on delayed engraftment after autologous bone marrow transplantation.

    abstract：:Very long delay to engraftment (or non-engraftment) was observed in eight patients presenting common immunological features, i.e. excess of blood and bone marrow lymphocytes coexpressing CD8 and CD57 (HNK1) antigens. They were therefore treated by CD8 immunotherapy. Such treatment induced a complete clearance of CD8+,...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Favrot M,Philip T,Combaret V,Lemerle J,Marie JP,Bernard A

    更新日期：1990-01-01 00:00:00

  • Growth, growth hormone and final height after BMT. Possible recovery of irradiation-induced growth hormone insufficiency.

    abstract：:The aim of the present study was to assess growth, final height, growth hormone (GH) secretion and growth factors after BMT including TBI in childhood. The median age of the 25 participants was 11.3 years at BMT, and a median of 7.5 years had elapsed since BMT. The median height standard deviation score (SDS) declined...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Holm K,Nysom K,Rasmussen MH,Hertz H,Jacobsen N,Skakkebaek NE,Krabbe S,Müller J

    更新日期：1996-07-01 00:00:00

  • The role of granulocyte colony-stimulating factor (G-CSF) in the post-transplant period.

    abstract：:The administration of G-CSF post transplant has been shown to accelerate the time to neutrophil engraftment. However, this does not necessarily translate into a meaningful clinical benefit to the patient. This randomized study was designed to determine the role of G-CSF following transplantation in patients with breas...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1038/sj.bmt.1703539

    authors： Hornedo J,Solá C,Solano C,López JJ,Alonso S,Lluch A,Ojeda B,Garcia-Conde J,Cortés-Funes H,SOLTI Group.

    更新日期：2002-05-01 00:00:00

  • Short-term ex vivo activation of splenocytes with anti-CD3 plus IL-2 and infusion post-BMT into mice results in in vivo expansion of effector cells with potent anti-lymphoma activity.

    abstract：:We investigated the proliferation and therapeutic utility of anti-CD3 activated splenocytes infused into mice following BMT. Using congenic mouse strains we demonstrated that splenocytes activated briefly ex vivo with anti-CD3 plus IL-2 (T-activated killer cells or T-AK) and infused intravenously following BMT had a g...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Katsanis E,Xu Z,Anderson PM,Dancisak BB,Bausero MA,Weisdorf DJ,Blazar BR,Ochoa AC

    更新日期：1994-10-01 00:00:00

  • Reduced-intensity allogeneic stem cell transplantation for patients aged 50 years or older with B-cell ALL in remission: a retrospective study by the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation.

    abstract：:We retrospectively assessed the outcome and pretransplantation predictors of the outcome in 118 patients aged ≥ 50 years who received fludarabine-containing reduced-intensity allo-SCT (RIST) for B-cell ALL in the first or second CR. Eighty patients received transplants from unrelated donors. Seventy-eight patients wer...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2013.140

    authors： Kanamori H,Mizuta S,Kako S,Kato H,Nishiwaki S,Imai K,Shigematsu A,Nakamae H,Tanaka M,Ikegame K,Yujiri T,Fukuda T,Minagawa K,Eto T,Nagamura-Inoue T,Morishima Y,Suzuki R,Sakamaki H,Tanaka J

    更新日期：2013-11-01 00:00:00

  • Patient education in allogeneic hematopoietic cell transplant: what patients wish they had known about quality of life.

    abstract：:Quality of life (QOL) is increasingly recognized as an important clinical outcome of hematopoietic cell transplantation (HCT), but patient education is often overlooked. The aim of the current qualitative study was to examine education regarding post-HCT QOL from the patient's perspective. Allogeneic HCT recipients pa...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2013.158

    authors： Jim HS,Quinn GP,Gwede CK,Cases MG,Barata A,Cessna J,Christie J,Gonzalez L,Koskan A,Pidala J

    更新日期：2014-02-01 00:00:00

  • rhG-CSF does not affect the phenotype of adult donor peripheral blood NK cells.

    abstract：:Considerable evidence in preclinical models as well as in human transplantation now suggests that donor-derived natural killer (NK) cells can contribute to alloimmune recognition of recipient residual tumour cells. This makes the NK cell population an attractive target for in vitro or in vivo manipulations, in order t...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1704711

    authors： Lassailly F,Sielleur I,Blaise D,Chabannon C

    更新日期：2005-01-01 00:00:00

  • Standardized parenteral alanyl-glutamine dipeptide supplementation is not beneficial in autologous transplant patients: a randomized, double-blind, placebo controlled study.

    abstract：:We conducted a controlled, double-blind study of parenteral glutamine supplementation in an unselected group of consecutive autologous transplant patients. Patients received 30 g of alanyl-glutamine dipeptide (Dipeptiven; Fresenius-Kabi, Bad Homburg, Germany) or glutamine-free amino acid solution i.v. from day +1 to d...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1038/sj.bmt.1703759

    authors： Pytlík R,Benes P,Patorková M,Chocenská E,Gregora E,Procházka B,Kozák T

    更新日期：2002-12-01 00:00:00

  • AlloHSCT in paediatric ALL and AML in complete remission: improvement over time impacted by accreditation?

    abstract：:Allogeneic hematopoietic stem cell transplantation (alloHSCT) has become a well-established treatment option for many patients suffering from malignant and non-malignant diseases. In the past decade, high-resolution HLA-typing, remission surveillance, pre-emptive immune intervention, and standardisation in supportive ...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/s41409-018-0341-z

    authors： Bakhtiar S,Salzmann-Manrique E,Hutter M,Krenn T,Duerken M,Faber J,Reinhard H,Kreyenberg H,Huenecke S,Cappel C,Bremm M,Pfirrmann V,Merker M,Barnbrock A,Schöning S,Willasch AM,Rettinger E,Soerensen J,Klingebiel TE,Jar

    更新日期：2019-05-01 00:00:00

  • Rescuing the neonatal brain from hypoxic injury with autologous cord blood.

    abstract：:Brain injury resulting from perinatal hypoxic-ischemic encephalopathy (HIE) is a major cause of acute mortality in infants and chronic neurologic disability in surviving children. Recent multicenter clinical trials demonstrated the effectiveness of hypothermia initiated within the first 6 postnatal hours to reduce the...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：10.1038/bmt.2012.169

    authors： Liao Y,Cotten M,Tan S,Kurtzberg J,Cairo MS

    更新日期：2013-07-01 00:00:00

  • Human herpesvirus 6 is an important pathogen in infectious lung disease after allogeneic bone marrow transplantation.

    abstract：:Two hundred and ten bronchoalveolar lavage (BAL) samples were obtained from 50 patients 10 days before and on defined days after allogeneic bone marrow transplantation (BMT). The samples were examined for human cytomegalovirus (HCMV) and human herpesvirus-6 (HHV-6) by polymerase chain reaction (PCR). Fifteen patients ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1702569

    authors： Buchbinder S,Elmaagacli AH,Schaefer UW,Roggendorf M

    更新日期：2000-09-01 00:00:00

  • Hematopoietic SCT modulates gut inflammation in experimental inflammatory bowel disease.

    abstract：:Hematopoietic SCT (HSCT) and high-dose chemotherapy are being explored as therapy for various human refractory immune-mediated conditions, including inflammatory bowel diseases (IBD). Nevertheless, the exact immunological mechanisms by which the BM cells (BMCs) or immunosuppression provide remission from these disease...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2010.6

    authors： Godoi DF,Cardoso CR,Ferraz DB,Provinciatto PR,Cunha FQ,Silva JS,Voltarelli JC

    更新日期：2010-10-01 00:00:00

  • Pneumoperitoneum without peritonitis after allogeneic peripheral blood stem cell transplantation.

    abstract：:Allogeneic blood stem cell transplantation is associated with multiple complications. We report a case of pneumoperitoneum without peritonitis associated with colonic pneumatosis in a patient who had undergone an allogeneic peripheral blood cell transplant ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1701255

    authors： de Magalhaes-Silverman M,Simpson J,Ball E

    更新日期：1998-06-01 00:00:00

  • Granulomatous pneumonitis following bone marrow transplantation.

    abstract：:We describe the rare occurrence of a granulomatous pneumonitis seen in a patient following allogeneic bone marrow transplantation. Interestingly sarcoidosis was diagnosed in the marrow donor less than a year after donating his bone marrow. ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1703192

    authors： Sundar KM,Carveth HJ,Gosselin MV,Beatty PG,Colby TV,Hoidal JR

    更新日期：2001-09-01 00:00:00

  • Cytokine treatment or accessory cells are required to initiate engraftment of purified primitive human hematopoietic cells transplanted at limiting doses into NOD/SCID mice.

    abstract：:Little is known about the cell types or mechanisms that underlie the engraftment process. Here, we have examined parameters affecting the engraftment of purified human Lin-CD34+CD38- normal and AML cells transplanted at limiting doses into NOD/SCID recipients. Mice transplanted with 500 to 1000 Lin-CD34+CD38- cord blo...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1701564

    authors： Bonnet D,Bhatia M,Wang JC,Kapp U,Dick JE

    更新日期：1999-02-01 00:00:00

  • Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization.

    abstract：:Plerixafor is an inhibitor of CXCR-4 (CXC chemokine receptor-4)/SDF (stromal cell-derived factor)-1 binding used in combination with granulocyte colony-stimulating factor (G-CSF) for mobilization of autologous peripheral blood hematopoietic stem cells (HSCs). We developed a data-generated, cost-saving decision-making ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2010.78

    authors： Costa LJ,Alexander ET,Hogan KR,Schaub C,Fouts TV,Stuart RK

    更新日期：2011-01-01 00:00:00

  • Allogeneic hematopoietic cell transplantation for metastatic breast cancer.

    abstract：:We reviewed 66 women with poor-risk metastatic breast cancer from 15 centers to describe the efficacy of allogeneic hematopoietic cell transplantation (HCT). Median follow-up for survivors was 40 months (range, 3-64). A total of 39 patients (59%) received myeloablative and 27 (41%) reduced-intensity conditioning (RIC)...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.bmt.1705940

    authors： Ueno NT,Rizzo JD,Demirer T,Cheng YC,Hegenbart U,Zhang MJ,Bregni M,Carella A,Blaise D,Bashey A,Bitran JD,Bolwell BJ,Elfenbein GJ,Fields KK,Freytes CO,Gale RP,Lazarus HM,Champlin RE,Stiff PJ,Niederwieser D

    更新日期：2008-03-01 00:00:00

  • Successful outcomes of second hematopoietic stem cell transplantation with total nodal irradiation and ATG conditioning for graft failure in adult patients with severe aplastic anemia.

    abstract：:Data regarding the optimal approach for second allogeneic hematopoietic stem cell transplantation (HSCT) after graft failure (GF) in acquired severe aplastic anemia (SAA) are still limited and heterogeneous. We examined 24 patients who underwent second HLA-matched sibling donor (MSD) peripheral blood HSCT for GF. The ...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/s41409-018-0154-0

    authors： Yahng SA,Park SS,Jeon YW,Yoon JH,Shin SH,Lee SE,Cho BS,Eom KS,Kim YJ,Lee S,Min CK,Kim HJ,Cho SG,Kim DW,Min WS,Lee JW

    更新日期：2018-10-01 00:00:00

  • Allo-SCT for  Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Française de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC).

    abstract：:Progression of Philadelphia-negative myeloproliferative (MPN) or myelodysplastic/myeloproliferative neoplasms (MDS/MPN) to acute myeloid leukemia (AML) is an adverse event in the course of the disease. Although allogeneic hematopoietic SCT (allo-SCT) is considered as the only curative therapy, few data exist on the ou...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究

    doi：10.1038/bmt.2014.31

    authors： Cahu X,Chevallier P,Clavert A,Suarez F,Michallet M,Vincent L,Vigouroux S,Blaise D,Mariette C,Bilger K,Robin M,Yakoub-Agha I,Peffault de Latour R,Mohty M

    更新日期：2014-06-01 00:00:00

  • Enteral budesonide in treatment for mild and moderate gastrointestinal chronic GVHD.

    abstract：:Budesonide (BUD) is a steroid with a low bioavailability, which has been used for the treatment of oral manifestations of chronic GVHD (cGVHD). We retrospectively evaluated the efficacy of BUD in the treatment of gastrointestinal cGVHD. Thirteen patients (median age 47 years) receiving BUD for the treatment of cGVHD a...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2008.209

    authors： Andree H,Hilgendorf I,Leithaeuser M,Junghanss C,Holzhueter S,Loddenkemper C,Steiner B,Freund M,Wolff D

    更新日期：2008-10-01 00:00:00

  • Pegfilgrastim compared with filgrastim for cytokine-alone mobilization of autologous haematopoietic stem and progenitor cells.

    abstract：:Haematopoietic stem and progenitor cells (HSPC) mobilization, using cytokine-alone, is a well-tolerated regimen with predictable mobilization kinetics. Single-dose pegfilgrastim mobilizes HSPC efficiently; however, there is surprisingly little comparative data on its use without chemotherapy for HSPC mobilization. Peg...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2012.145

    authors： Herbert KE,Gambell P,Link EK,Mouminoglu A,Wall DM,Harrison SJ,Ritchie DS,Seymour JF,Prince HM

    更新日期：2013-03-01 00:00:00

  • Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/Austrian Pediatric Bone Marrow Transplantation Group.

    abstract：:Patients with primary metastatic or recurrent rhabdomyosarcoma (RMS) have a very poor prognosis. Since high-dose chemotherapy (HDC) +/- TBI was thought to improve survival, many centers performed this therapy using different types of hematopoietic rescue (auto BM or PBSC, allo BM). This is a retrospective, multi-cente...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究

    doi：10.1038/sj.bmt.1700628

    authors： Koscielniak E,Klingebiel TH,Peters C,Hermann J,Burdach ST,Bender-Götze C,Müller-Weihrich ST,Treuner J

    更新日期：1997-02-01 00:00:00

  • Evaluation of pretransplant influenza vaccination in hematopoietic SCT: a randomized prospective study.

    abstract：:Pretransplant influenza vaccination of the donor or allogeneic hematopoietic SCT (HSCT) candidate was evaluated in a randomized study. One hundred and twenty-two HSCT recipients and their donors were assigned to three randomization groups: no pretransplant vaccination (n=38), donor pretransplant vaccination (n=44) or ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1038/bmt.2015.47

    authors： Ambati A,Boas LS,Ljungman P,Testa L,de Oliveira JF,Aoun M,Colturato V,Maeurer M,Machado CM

    更新日期：2015-06-01 00:00:00

  • Erythema exsudativum multiforme induced by granulocyte colony-stimulating factor in an allogeneic peripheral blood stem cell donor.

    abstract：:We describe a healthy peripheral blood stem cell (PBSC) donor who developed a cutaneous reaction, erythema exsudativum multiforme, during the administration of granulocyte colony-stimulating factor (G-CSF) for mobilization. The cutaneous lesions were located on his hips, apart from the site of G-CSF injection. Treatme...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1702501

    authors： Mori T,Sato N,Watanabe R,Okamoto S,Ikeda Y

    更新日期：2000-07-01 00:00:00

  • The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia.

    abstract：:We treated 12 patients with chronic myelogenous leukemia (CML) with a low-intensity preparative regimen followed by allogeneic stem cell transplantation in an attempt to confer a curative graft-versus-leukemia (GVL) effect with minimum morbidity. Seven patients in first chronic phase (CP1) and five in second chronic p...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.bmt.1704231

    authors： Sloand E,Childs RW,Solomon S,Greene A,Young NS,Barrett AJ

    更新日期：2003-11-01 00:00:00

  • Evaluation of a monoclonal IgM antibody for purging of bone marrow for autologous transplantation.

    abstract：:A monoclonal antibody of the IgM class, reacting with the CD9 (p24) antigen is described. The antibody (FMC27) is cytotoxic against cells of the common type of acute lymphoblastic leukaemia (c-ALL), giving killing at higher dilutions than an IgG antibody (FMC8) against the same antigen. FMC27 and FMC8 recognise differ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Zola H,Potter A,Neoh SH,Juttner CA,Haylock DN,Rice AM,Favaloro EJ,Kabral A,Bradstock KF

    更新日期：1987-02-01 00:00:00